Covestro Begins Local Medical-Grade TPU Production in Taiwan
ECONOMY & POLICY

Covestro Begins Local Medical-Grade TPU Production in Taiwan

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.

This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.

Meeting Global Standards, Serving Regional Needs

Manufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.

Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”

Designed for Advanced Medical Use

Desmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.

The material’s benefits include:

  • Biocompatibility for patient-contact use
  • High clarity for medical observation
  • Kink resistance for uninterrupted fluid flow
  • Excellent chemical and abrasion resistance
  • Superior flexibility and dimensional stability

Additionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.

Strengthening Regional Infrastructure

The Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”

Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.Meeting Global Standards, Serving Regional NeedsManufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”Designed for Advanced Medical UseDesmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.The material’s benefits include:Biocompatibility for patient-contact useHigh clarity for medical observationKink resistance for uninterrupted fluid flowExcellent chemical and abrasion resistanceSuperior flexibility and dimensional stabilityAdditionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.Strengthening Regional InfrastructureThe Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Related Stories

Gold Stories

Next Story
Infrastructure Energy

Asian Energy Services Q1 FY27 PAT Rises 129 Per Cent

Asian Energy Services Limited reported a 129 per cent year-on-year rise in net profit to Rs 128 million for Q1 FY27, compared with the corresponding quarter last year.Revenue increased 135 per cent year-on-year to Rs 2.71 billion, supported by continued momentum across its services business, disciplined execution and contributions from domestic and international operations. EBITDA grew 81 per cent year-on-year during the quarter.As of June 30, 2026, the company’s standalone order book stood at Rs 17.54 billion, with around 60 per cent coming from oil and gas services and 40 per cent from min..

Next Story
Infrastructure Urban

BioBTX to Build First Commercial-Scale Circular Chemicals Plant

Dutch circular chemistry technology developer BioBTX is building what it says will be the world’s first commercial-scale plant to convert mixed plastic waste into high-quality aromatic chemicals using its proprietary Integrated Catalytic Cracking Process (ICCP) technology.The facility will be built at Chemical Park Delfzijl on the northern coast of the Netherlands and is expected to create 35 jobs. Covestro, which has been a shareholder and strategic partner of BioBTX since 2024, holds a mid-single-digit million-euro investment in the company.BioBTX’s ICCP technology uses catalytic pyrolys..

Next Story
Real Estate

Awfis Q1 FY27 PAT Jumps 140% as Revenue Rises 27%

Awfis Space Solutions reported a 140 per cent year-on-year rise in consolidated profit after tax (PAT) to Rs 240 million for Q1 FY27, compared with Rs 100 million in the corresponding quarter last year.Revenue from operations increased 27 per cent to Rs 4.25 billion from Rs 3.35 billion, while EBITDA rose 28 per cent to Rs 1.62 billion. EBITDA margin improved to 38.2 per cent from 37.8 per cent. Profit before tax increased 135 per cent to Rs 240 million.The company's co-working business recorded 27 per cent year-on-year growth, supported by demand from enterprises, Global Capability Centres (G..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement